| Similar Articles |
|---|
 |
The Motley Fool
October 26, 2010
Travis Hoium |
ARIAD Pharmaceuticals Shares Plunged: What You Need to Know A day after shares pop, the company announced a stock offering at $3.70 per share, and shares drop.   |
The Motley Fool
October 15, 2009
Brian Orelli |
This Partnership Will Go No Further Wyeth and Progenics call it quits. |
The Motley Fool
February 24, 2011
Brian D. Pacampara |
Salix Pharmaceuticals Shares Plunged: What You Need to Know Shares of Salix Pharmaceuticals plummeted more than 20% after the company said it expects the Food and Drug Administration to deny its bid to gain expanded approval for its gastrointestinal antibiotic Xifaxan. |
The Motley Fool
July 23, 2007
Brian Lawler |
Progenics Gets Back In the Game Being the first approved to market an oral compound to treat one of the more painful side effects from opioid use will be a boon to whichever drugmaker can reach this goal. With the competitior Adolor looking more likely to be out of this race, Progenics is in the pole position once again. |
The Motley Fool
May 23, 2008
Brian Orelli |
Progenics' Mixed Trial Data Progenics Pharmaceuticals and marketing partner Wyeth release both positive and negative clinical trial data. |
The Motley Fool
November 28, 2008
Brian Orelli |
Will Patients Reject This Injection? Wyeth and Progenics release good trial data, but will patients want their constipation drug? |
The Motley Fool
September 22, 2009
Brian Orelli |
Nektar Tastes Sweet Nektar is getting an up-front payment of $125 million and AstraZeneca is taking over development of two of its compounds. |
The Motley Fool
April 25, 2008
Brian Orelli |
Progenics' Double Dose of Good News Its lead drug gets FDA approval and a positive EU recommendation. |
The Motley Fool
March 9, 2007
Brian Lawler |
Progenics Gets Backed Up Progenics Pharmaceutics and drugmaker giant Wyeth announced a delay in one of their methylnaltrexone programs. Investors, take note. |
Chemistry World
March 25, 2015
Phillip Broadwith |
Valeant heads off Endo bid for Salix Valeant has flexed its acquisitive muscles to head off a rival bid for gastroenterology specialist Salix Pharmaceuticals. |
The Motley Fool
June 24, 2005
Brian Gorman |
Salix's Strange Deal Salix announced that it will buy Inkine in an all-stock acquisition valued at $190 million. At first glance, the two companies appear to be a good strategic fit, since both specialize in marketing gastrointestinal drugs. However, the agreement seems to have more weaknesses than strengths. |
The Motley Fool
April 2, 2007
Brian Lawler |
Progenics Submits for Its Future Progenics submits a New Drug Application for its lead compound. Whether the sales and royalty revenue that methylnaltrexone can bring in will be enough to support its current valuation is still in doubt. |
The Motley Fool
May 10, 2011
Frank Vinluan |
Salix Sued by Partner for "Breach" Over HIV-Associated Drug Who will take this blockbuster drug to market? |
The Motley Fool
July 25, 2008
Brian Orelli |
Generic Heartburn at Wyeth Revenue from its heartburn drug Protonix dropped 59% year over year after Teva Pharmaceuticals and Sun Pharmaceuticals launched their generic versions of the drug. |
The Motley Fool
February 25, 2011
Brian Orelli |
When the Companies Know, Investors Should, Too Why don't more companies preannounce FDA rejections? |
Chemistry World
February 23, 2015
Phillip Broadwith |
Valeant to buy Salix for $14.5bn Serial acquirer Valeant has agreed to buy gastroenterology specialist Salix Pharmaceuticals for $14.5 billion |
The Motley Fool
November 30, 2010
Brian Orelli |
Soros Is Buying Health Care. Should You? Some but not all of his picks look good to me. |
American Family Physician
February 1, 2006 |
Chronic Constipation in Your Child An informative patient hand-out: What is constipation?... How common is chronic constipation... Why does my child have constipation?... etc. |
Chemistry World
May 26, 2015
Phillip Broadwith |
Endo to buy Par as generics consolidation continues Irish-headquartered firm Endo Pharmaceuticals has agreed to buy private US firm Par Pharmaceuticals in a deal worth around $8 billion in a combination of cash, shares and assumed debt. |
BusinessWeek
November 21, 2005
Gene G. Marcial |
Salix Pharmaceuticals: What The Gut Tells You The small fry in gastrointestinal drugs is a pure play in that growing market. |
